Te Chun Hsia

Dr. Te Chun Hsia

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2017 in Lung Cancer
Verified
Journal Article
Closed access
YSYi-Cheng Shen
Yi-Cheng Shen
GTGuan-Chin Tseng
Guan-Chin Tseng
CTChih-Yeh Tu
Chih-Yeh Tu
WCWei-Chun Chen
Wei-Chun Chen
WLWei-Chih Liao
Wei-Chih Liao
THTe Chun Hsia
Te Chun Hsia

19 February 2024 in BMC Cancer
Verified
Journal Article
Open access
PDF file
WCWen-Chien Cheng
Wen-Chien Cheng
Lim Chih-ChenLim Chih-Chen
Lim Chih-Chen
WLWei-Chih Liao
Wei-Chih Liao
YLYu-Chao Lin
Yu-Chao Lin
CCChia-Hung Chen
Chia-Hung Chen
THTe Chun Hsia
Te Chun Hsia
Objectives: The irreversible epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) afatinib and dacomitinib are approved for first-line treatment ofEGFRmutation-positive non-small cell lung cancer (NSCLC). We aimed to compare the efficacy and safety of afatinib and dacomitinib in this setting.Materials and methods: Between September 2020 and March 2023, we retrospectively recruited patients diagnosed with advanced-stageEGFR-mutant NSCLC who were treated with first-line irreversible EGFR-TKIs. The enrolled patients were assigned to two groups based on whether they received afatinib or dacomitinib.Results: A total of 101 patients were enrolled in the study (70 to afatinib and 31 to dacomitinib). The partial response rates (PR) for first-line treatment with afatinib and dacomitinib were 85.7 and 80.6% (p = 0.522). The median progression-free survival (PFS) (18.9 vs. 16.3 months,p = 0.975) and time to treatment failure (TTF) (22.7 vs. 15.9 months,p = 0.324) in patients with afatinib and dacomitinib treatment were similar. There was no significant difference observed in the median PFS (16.1 vs. 18.9 months,p = 0.361) and TTF (32.5 vs. 19.6 months,p = 0.182) between patients receiving the standard dose and those receiving the reduced dose. In terms of side effects, the incidence of diarrhea was higher in the afatinib group (75.8% vs. 35.5%,p < 0.001), while the incidence of paronychia was higher in the dacomitinib group (58.1% vs. 31.4%,p = 0.004). The PFS (17.6 vs. 24.9 months,p = 0.663) and TTF (21.3 vs. 25.1 months,p = 0.152) were similar between patients younger than 75 years and those older than 75 years.Conclusion: This study showed that afatinib and dacomitinib had similar effectiveness and safety profiles. However, they have slightly different side effects. Afatinib and dacomitinib can be safely administered to patients across different age groups with appropriate dose reductions.

15 June 2023 in Environmental Toxicology
Verified
Journal Article
Closed access
TLTzu‐Shun Lin
Tzu‐Shun Lin
WHWan‐Nei Huang
Wan‐Nei Huang
JYJiun‐Long Yang
Jiun‐Long Yang
SPShu-Fen Peng
Shu-Fen Peng
KLKuo‐Ching Liu
Kuo‐Ching Liu
AHAn‐Cheng Huang
An‐Cheng Huang

1 December 2014
Verified
Journal Article
Closed access
THTe Chun Hsia
Te Chun Hsia
WCWen-Shin Chang
Wen-Shin Chang
SLShinn-Jye Liang
Shinn-Jye Liang
WCWei-Chun Chen
Wei-Chun Chen
CTChih-Yen Tu
Chih-Yen Tu
DBDa-Tian Bau
Da-Tian Bau

23 May 2022 in BMC Cancer
Verified
Journal Article
Open access
PDF file
CCChieh-Lung Chen
Chieh-Lung Chen
SWSing-Ting Wang
Sing-Ting Wang
WLWei-Chih Liao
Wei-Chih Liao
CCChia-Hung Chen
Chia-Hung Chen
CTChih-Yen Tu
Chih-Yen Tu
WCWen Chien Cheng
Wen Chien Cheng
The addition of anti-angiogenesis drugs to epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor (TKI) or chemotherapy in patients with EGFR-mutant non–small cell lung cancer (NSCLC) can improve disease control. We conducted a study to evaluate the efficacy of combination therapeutic strategies and identify patients who could benefit from combination therapy. This study enrolled patients with stage IV EGFR-mutant NSCLC treated with first-line EGFR-TKIs between January 2014 and December 2020. We divided patients into three groups: patients who received an anti-angiogenesis drug as first-line combination therapy, those who received an anti-angiogenesis drug as further-line combination therapy, and those with no anti-angiogenesis therapy. A total of 204 patients were enrolled in the final analysis. Progression-free survival (PFS) in patients receiving first-line anti-angiogenesis plus EGFR-TKI combination therapy was longer (18.2 months) than those treated with first-line EGFR-TKI monotherapy (10.0 months for both, p < 0.001). No difference in overall survival (OS) was observed among these three groups (30.5 vs. 42.6 vs. 33.7 months, p = 0.326). Multivariate Cox regression analysis revealed L858R mutation, pleural, liver, and bone metastasis as independent prognostic factors for poor OS. However, the addition of anti-angiogenesis therapy to patients with these poor prognostic factors improved OS to levels similar to those without these poor prognostic factors. First-line combination EGFR-TKI plus anti-angiogenesis therapy improves PFS in patients with stage IV EGFR-mutant NSCLC. Adding an anti-angiogenesis drug at any line to patients harboring L858R mutation with pleural, liver, or bone metastases can provide survival benefits.

1 July 2015
Verified
Journal Article
Closed access
HCHung-Jen Chen
Hung-Jen Chen
WCWen-Shin Chang
Wen-Shin Chang
THTe Chun Hsia
Te Chun Hsia
CMChia-En Miao
Chia-En Miao
WCWei-Chun Chen
Wei-Chun Chen
DBDa-Tian Bau
Da-Tian Bau